A Lancet commentary argues that shortening direct-acting antiviral treatment for hepatitis C could speed elimination, weighing the 12-week sofosbuvir–velpatasvir regimen against the 8-week glecaprevir–pibrentasvir option.
Shorter Hepatitis C Regimens Seen as Key to Elimination Push
A Lancet commentary argues that shortening direct-acting antiviral treatment for hepatitis C could speed elimination, weighing the 12-week sofosbuvir–velpatasvir regimen against the 8-week glecaprevir–pibrentasvir option.
![[Comment] Shortening treatment to accelerate hepatitis C elimination](https://nbg1.your-objectstorage.com/ckln/image-assets/c32cd40c34a7afb6cc3b22a01030fcb66bcd171e260ddc7fc2458394fece7b3e.jpg)
Hepatitis C virus · Wikimedia — licence per file · rights
This item was produced with AI assistance under the editorial responsibility of Haydamax OÜ.
Monitoring item. The full text is not distributed. Extract and source below.